Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cognitive screening in Multiple Sclerosis: the Five-Point Test as a substitute for the PASAT in measuring executive function.
Patients smoking cannabis are risking their health.
Immune response in peripheral axons delays disease progression in SOD1(G93A) mice.
Unilateral olfactory sensitivity in multiple sclerosis.
Letter to the Editor: The Emerging Role of Pharmacists in the Multidisciplinary Care of Patients with Multiple Sclerosis.
Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis.
Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies.
Influence of a low dose of silver nanoparticles on cerebral myelin and behavior of adult rats.
The effect of vibrotactile biofeedback of trunk sway on balance control in multiple sclerosis.
Myeloid cells - targets of medication in multiple sclerosis.
Corrigendum: Oligodendrocyte, Astrocyte and Microglia Crosstalk in Myelin Development, Damage, and Repair.
CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?
Understanding staff made my return to work possible.
Regenerative Capacity of Macrophages for Remyelination.
Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice.
Coactivation of Lower Limb Muscles during Gait in Patients with Multiple Sclerosis.
Neurotrophins' Modulation by Olive Polyphenols.
The role of the wnt canonical signaling in neurodegenerative diseases.
A Case of Optic Neuritis Concomitant with Pituitary Tumor during Pregnancy.
Differential processing of autoantigens in lysosomes from human monocyte-derived and peripheral blood dendritic cells.
Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
Idiopathic Transverse Myelitis Mimicking an Intramedullary Spinal Cord Tumor.
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: No.
Validation of the Oxford Participation and Activities Questionnaire.

Pages